Prelude Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.9K	Sell	15,670 -11,388	-42%	-$36.1K	﹤0.01%	1134
2025 Q4	$100K	Sell	27,058 -38,269	-59%	-$124K	0.01%	1185
2025 Q3	$173K	Sell	65,327 -200,261	-75%	-$387K	0.01%	980
2025 Q2	$261K	Buy	265,588 +97,283	+58%	+$97.4K	0.03%	673
2025 Q1	$242K	Buy	168,305 +48,630	+41%	+$89.6K	0.02%	817
2024 Q4	$263K	Sell	119,675 -123,172	-51%	-$287K	0.02%	859
2024 Q3	$401K	Sell	242,847 -28,042	-10%	-$56.6K	0.03%	720
2024 Q2	$601K	Buy	270,889 +242,926	+869%	+$571K	0.05%	464
2024 Q1	$74.9K	Sell	27,963 -1,828	-6%	-$4.44K	0.01%	1228
2023 Q4	$89.1K	Buy	+29,791	New	+$38.6K	0.01%	1036
2018 Q1	–	Sell	-500	Closed	-$33K	–	1579
2017 Q4	$33K	Buy	500 +400	+400%	+$21.5K	﹤0.01%	1023
2017 Q3	$5K	Sell	100 -100	-50%	-$4.82K	﹤0.01%	1504
2017 Q2	$9K	Buy	+200	New	+$7.36K	﹤0.01%	1409
2015 Q4	–	Hold	0	–	–	–	1523
2015 Q3	–	Hold	0	–	–	–	1571